<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30257595</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1551-4005</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>17</Volume>                    <Issue>17</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Cell cycle (Georgetown, Tex.)</Title>                <ISOAbbreviation>Cell Cycle</ISOAbbreviation>            </Journal>            <ArticleTitle>A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX.</ArticleTitle>            <Pagination>                <MedlinePgn>2091-2100</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384101.2018.1515551</ELocationID>            <Abstract>                <AbstractText>Here, we wish to propose a new systematic approach to cancer therapy, based on the targeting of mitochondrial metabolism, especially in cancer stem cells (CSCs). In the future, we envision that anti-mitochondrial therapy would ultimately be practiced as an add-on to more conventional therapy, largely for the prevention of tumor recurrence and cancer metastasis. This mitochondrial based oncology platform would require a panel of FDA-approved therapeutics (e.g. Doxycycline) that can safely be used to inhibit mitochondrial OXPHOS and/or biogenesis in CSCs. In addition, new therapeutics that target mitochondria could also be developed, to optimize their ability to eradicate CSCs. Finally, in this context, mitochondrial-based biomarkers (i.e. &quot;Mito-signatures&quot;) could be utilized as companion diagnostics, to identify high-risk cancer patients at diagnosis, facilitating the early detection of tumor recurrence and the prevention of treatment failure. In summary, we suggest that new clinical trials are warranted to test and possibly implement this emerging treatment strategy, in a variety of human cancer types. This general approach, using FDA-approved antibiotics to target mitochondria, was effective in killing CSCs originating from many different cancer types, including DCIS, breast (ER(+) and ER(-)), prostate, ovarian, lung and pancreatic cancers, as well as melanoma and glioblastoma, among others. Thus, we propose the term MITO-ONC-RX, to describe this anti-mitochondrial platform for targeting CSCs. The use of re-purposed FDA-approved drugs will undoubtedly help to accelerate the clinical evaluation of this approach, as these drugs can move directly into Phase II clinical trials, saving considerable amounts of time (10-15Â y) and billions in financial resources.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Sotgia</LastName>                    <ForeName>Federica</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>a Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC) , University of Salford , Greater Manchester , UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ozsvari</LastName>                    <ForeName>Bela</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>a Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC) , University of Salford , Greater Manchester , UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fiorillo</LastName>                    <ForeName>Marco</ForeName>                    <Initials>M</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8055-3259</Identifier>                    <AffiliationInfo>                        <Affiliation>a Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC) , University of Salford , Greater Manchester , UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>b Department of Pharmacy, Health and Nutritional Sciences , University of Calabria , Rende , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>De Francesco</LastName>                    <ForeName>Ernestina Marianna</ForeName>                    <Initials>EM</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2810-6128</Identifier>                    <AffiliationInfo>                        <Affiliation>a Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC) , University of Salford , Greater Manchester , UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>b Department of Pharmacy, Health and Nutritional Sciences , University of Calabria , Rende , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bonuccelli</LastName>                    <ForeName>Gloria</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>a Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC) , University of Salford , Greater Manchester , UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lisanti</LastName>                    <ForeName>Michael P</ForeName>                    <Initials>MP</Initials>                    <AffiliationInfo>                        <Affiliation>a Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC) , University of Salford , Greater Manchester , UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>26</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Cell Cycle</MedlineTA>            <NlmUniqueID>101137841</NlmUniqueID>            <ISSNLinking>1551-4005</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2014 Nov 30;5(22):11029-37</RefSource>                <PMID Version="1">25415228</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Opin Microbiol. 2014 Dec;22:38-48</RefSource>                <PMID Version="1">25306530</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Aging (Albany NY). 2017 Dec 16;9(12):2610-2628</RefSource>                <PMID Version="1">29253841</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Sep 24;8(45):78340-78350</RefSource>                <PMID Version="1">29108233</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cold Spring Harb Perspect Biol. 2012 Sep 01;4(9):a011403</RefSource>                <PMID Version="1">22952398</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2013 Sep 19;501(7467):328-37</RefSource>                <PMID Version="1">24048065</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Jun 10;6(16):14005-25</RefSource>                <PMID Version="1">26087309</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Jun 12;8(34):56126-56142</RefSource>                <PMID Version="1">28915578</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Jul 7;8(40):67457-67472</RefSource>                <PMID Version="1">28978045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Mar 28;8(13):20667-20678</RefSource>                <PMID Version="1">28223550</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2012 Jan 18;481(7381):306-13</RefSource>                <PMID Version="1">22258609</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem J. 2018 May 9;475(9):1611-1634</RefSource>                <PMID Version="1">29743249</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Crit Rev Clin Lab Sci. 2016;53(1):40-51</RefSource>                <PMID Version="1">26397062</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Jun 9;8(40):67269-67286</RefSource>                <PMID Version="1">28978032</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Mar 10;6(7):4585-601</RefSource>                <PMID Version="1">25671304</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Transl Med. 2013 Jul 3;5(192):192ra85</RefSource>                <PMID Version="1">23825301</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Aging (Albany NY). 2017 Oct 27;9(10):2098-2116</RefSource>                <PMID Version="1">29080556</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World J Stem Cells. 2015 Mar 26;7(2):418-27</RefSource>                <PMID Version="1">25815125</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Jun 20;6(17):14777-95</RefSource>                <PMID Version="1">26087310</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Feb 7;8(6):9868-9884</RefSource>                <PMID Version="1">28039467</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>IUBMB Life. 2015 Sep;67(9):687-93</RefSource>                <PMID Version="1">26337609</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Aging (Albany NY). 2018 Feb 19;10(2):229-240</RefSource>                <PMID Version="1">29466249</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2011 Jan 20;469(7330):314-22</RefSource>                <PMID Version="1">21248838</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Clin Oncol. 2017 Jan;14(1):11-31</RefSource>                <PMID Version="1">27141887</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Jun 7;7(23):34084-99</RefSource>                <PMID Version="1">27136895</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Philos Trans R Soc Lond B Biol Sci. 2015 Sep 26;370(1678):20140330</RefSource>                <PMID Version="1">26323761</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Opin Cell Biol. 2017 Oct;48:47-53</RefSource>                <PMID Version="1">28605656</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Cancer Biol. 2017 Dec;47:18-28</RefSource>                <PMID Version="1">28673608</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Jul 27;8(40):68730-68745</RefSource>                <PMID Version="1">28978152</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer. 2017 Feb 16;16(1):41</RefSource>                <PMID Version="1">28209166</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Cycle. 2015;14(1):86-98</RefSource>                <PMID Version="1">25483072</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2016 May 24;18(1):55</RefSource>                <PMID Version="1">27220421</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Cycle. 2015;14(22):3527-32</RefSource>                <PMID Version="1">25970790</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Aug 6;8(40):66925-66939</RefSource>                <PMID Version="1">28978006</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Reprod Med. 2013 Jan;31(1):5-13</RefSource>                <PMID Version="1">23329631</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Mar 10;6(7):4569-84</RefSource>                <PMID Version="1">25625193</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2016 Jun 14;114(12):1305-12</RefSource>                <PMID Version="1">27219018</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 1976 Oct 1;194(4260):23-8</RefSource>                <PMID Version="1">959840</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochim Biophys Acta Bioenerg. 2018 Sep;1859(9):984-996</RefSource>                <PMID Version="1">29626418</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Oct 13;6(31):30472-86</RefSource>                <PMID Version="1">26421710</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Oncol. 2017 Jun;44(3):198-203</RefSource>                <PMID Version="1">29248131</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Aging (Albany NY). 2016 Aug;8(8):1593-607</RefSource>                <PMID Version="1">27344270</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2018 Jan 19;9(17):13254-13275</RefSource>                <PMID Version="1">29568355</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Mar 2;8(12):20309-20327</RefSource>                <PMID Version="1">28411284</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Mito-signatures</Keyword>            <Keyword MajorTopicYN="N">Mito-therapeutics</Keyword>            <Keyword MajorTopicYN="N">Mitochondria</Keyword>            <Keyword MajorTopicYN="N">Mitoflavoscins</Keyword>            <Keyword MajorTopicYN="N">Mitoketoscins</Keyword>            <Keyword MajorTopicYN="N">Mitoriboscins</Keyword>            <Keyword MajorTopicYN="N">drug discovery</Keyword>            <Keyword MajorTopicYN="N">mito-biomarkers</Keyword>            <Keyword MajorTopicYN="N">oncology platform</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30257595</ArticleId>            <ArticleId IdType="doi">10.1080/15384101.2018.1515551</ArticleId>            <ArticleId IdType="pmc">PMC6226227</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>